Capricor Therapeutics (CAPR) Research & Development (2010 - 2026)

Capricor Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• In Q1 2026, Research & Development rose 44.73% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $92.9 million (up 60.73% YoY), while the FY2025 annual figure was $84.5 million, up 69.02% from the prior year.
• Research & Development was $27.4 million for Q1 2026 at Capricor Therapeutics, up from $23.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $27.4 million in Q1 2026 to a low of $5.0 million in Q2 2022.
• Historically, Research & Development has averaged $12.9 million across 5 years, with a median of $11.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Research & Development jumped 120.17% in 2022, then grew 17.74% in 2024.
• A 5-year view of Research & Development shows it stood at $6.2 million in 2022, then surged by 59.63% to $9.9 million in 2023, then jumped by 46.45% to $14.6 million in 2024, then jumped by 58.94% to $23.2 million in 2025, then advanced by 18.24% to $27.4 million in 2026.
• The last three Research & Development figures came in at $27.4 million (Q1 2026), $23.2 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.